Class of 2014


HemoGenyx is a biopharmaceutical company developing a new treatment for blood diseases, such as leukemia, lymphoma and bone marrow (“BM”) failure. The Company leverages a special class of cells that can generate cancer-free, patient-matched blood stem cells. These cancer-free cells can then be used in BM and blood (hematopoietic) stem cell (“HSC”) transplants, which will improve the efficacy of BM/HSC transplants and make BM/HSC transplants a viable treatment option for many patients that wouldn’t otherwise be able to find a matching donor.​



Dr. Vladislav Sandler
Co-founder and CEO
Alexis Sandler
Co-founder and COO


What was the inspiration for your company?

Alexis Sandler: Dr. Vladislav Sandler’s work in the lab, the results of which are at the heart of the HemoGenyx business, was an outgrowth of his own personal experience with the loss of close relatives from blood diseases like leukemia and lymphoma. Thus, the inspiration for HemoGenyx is the widespread need for a more effective treatment for such blood diseases.

What did you know about Buffalo before registering for the competition?

AS: We were certainly familiar with Buffalo’s professional sports teams, the Bills and the Sabres, and, of course, its proximity to Niagara Falls. We were also quite fond of buffalo wings. Thanks to the 43North competition, we’ve now know so much more about what the city has to offer.